Clinical trial
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous…
NCT00255801 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00255801 |
|---|---|
| Title | Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma |
| Official title | Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil®) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin®) |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Tibotec Pharmaceutical Limited Industry M.D. Anderson Cancer Center NYU Langone Health Hackensack Meridian Health Roswell Park Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Targretin® (bexarotene), pegylated liposomal doxorubicin hydrochloride |
| Enrollment | 37 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2017 |
| Completion | Oct 1, 2017 |
| First posted | Nov 21, 2005 |
| Last update posted | Aug 16, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: